Birch pollen allergen immunotherapy reprograms nasal epithelial transcriptome and recovers microbial diversity - 06/06/19
Doi : 10.1016/j.jaci.2019.02.002
Tanzeela Hanif, MSci a, ∗, Kishor Dhaygude, MSci a, ∗, Matti Kankainen, PhD b, c, Jutta Renkonen, DDS a, Pirkko Mattila, PhD b, Teija Ojala, PhD d, Sakari Joenväärä, MSci a, Mika Mäkelä, MD e, Anna Pelkonen, MD, PhD e, Paula Kauppi, MD, PhD e, Tari Haahtela, MD e, Risto Renkonen, MD a, f, ‡, Sanna Toppila-Salmi, MD, PhD a, e, ‡ 
a Haartman Institute, University of Helsinki, Helsinki, Finland
b Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
c Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
d Department of Pharmacology, University of Helsinki, Helsinki, Finland
e Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
f HUSLAB, Helsinki University Hospital, Helsinki, Finland
| The study was supported in part by research grants from the Finnish Association of Otorhinolaryngology and Head and Neck Surgery, Finnish Medical Foundation, the Finnish Medical Society Duodecim, the Finnish Society of Allergology and Immunology, the Jane and Aatos Erkko Foundation, the Finnish Cultural Foundation, State funding for university-level health research (grant no. TYH2018103), the Paulo Foundation, the Sigrid Jusélius Foundation, the Tampere Tuberculosis Foundation, the Väinö and Laina Kivi Foundation, the Yrjö Jahnsson Foundation, the Academy of Finland (grant nos. 292605 and 292635), and Business Finland (grant no. Dnro 6113/31/2016). |
|
| Disclosure of potential conflict of interest: S. Toppila-Salmi has acted as a paid consultant for Mylan Laboratories Ltd, Biomedical systems Ltd, and Roche Products Ltd. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2019
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 143 - N° 6
P. 2293 - juin 2019 Retour au numéro
Article précédent
- Therapeutic potential of D prostanoid receptor 1 signal enhancement in a murine model of food allergy
- Tatsuro Nakamura, Rina Hirai, Yuri Tachibana, Sakura Masuko, Nanae Nagata, Takahisa Murata
- A combined immunodeficiency with severe infections, inflammation, and allergy caused by ARPC1B deficiency
- Stefano Volpi, Maria Pia Cicalese, Paul Tuijnenburg, Anton T.J. Tool, Eloy Cuadrado, Marwan Abu-Halaweh, Hamid Ahanchian, Raed Alzyoud, Zeynep Coban Akdemir, Federica Barzaghi, Alexander Blank, Bertrand Boisson, Cristina Bottino, Immacolata Brigida, Roberta Caorsi, Jean-Laurent Casanova, Sabrina Chiesa, Ivan Kingyue Chinn, Gregor Dückers, Anselm Enders, Hans Christian Erichsen, Lisa R. Forbes, Tomasz Gambin, Marco Gattorno, Ehsan Ghayoor Karimiani, Silvia Giliani, Michael S. Gold, Eva-Maria Jacobsen, Machiel H. Jansen, Jovanka R. King, Ronald M. Laxer, James R. Lupski, Emily Mace, Stefania Marcenaro, Reza Maroofian, Alexander B. Meijer, Tim Niehues, Luigi D. Notarangelo, Jordan Orange, Ulrich Pannicke, Chris Pearson, Paolo Picco, Patrick J. Quinn, Ansgar Schulz, Filiz Seeborg, Asbjørg Stray-Pedersen, Hasan Tawamie, Ester M.M. van Leeuwen, Alessandro Aiuti, Rae Yeung, Klaus Schwarz, Taco W. Kuijpers
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?